Abstract
The aim of our study was to develop a new scale for predicting clinical outcome in newborns with sepsis, taking into account the information about depth of metabolic disorders.Methods. Design of study — retrospective observational single-center study. Medical cards data of 163 newborns with sepsis were included in analysis. To measure the predictive value of the analyzed clinical and laboratory signs we used the Kullback measure. The clinical outcome of the disease was determined as the response function: survived or died.Results. An analysis of the predictive value of the clinical and laboratory parameters of in newborns with sepsis was made, the threshold values of the most informative indicators were developed, which were: the number of blood platelets, the level of total blood protein, body weight and the number of blood neutrophils. The Clinical and Laboratory Condition Index for Newborns scale has been developed, which takes into account the depth of metabolic disorders. ROC analysis (Area Under Curve — 0,723) and the information method (information coefficient 0.992) showed that the Clinical and Laboratory Condition Index score can be used in the intensive care unit to predict the risk negative clinical outcome and evaluate the effectiveness of treatment in infants with organ dysfunction caused by systemic infection.Conclusion. New Clinical and Laboratory Condition Index score scale allows to predict the development of negative outcome of sepsis in newborns taking into account the depth of metabolic disorders in newborns with sepsis.
Highlights
The concentration of unsaturated fatty acids in group 1 when compared with group 2 were significantly increased — C5:1, C8:1, C 14:1, C14:2, C16:1, C18:1
There is an increase in the content of serum unsaturated fatty acids compared with children with pneumonia and healthy newborns
Analytical and bioanalytical chemistry. 2016, Vol 408, no. 27, pp. 7641–7649
Summary
The fatty acids levels were determined by tandem mass spectrometry method on a Quattro micro MSMS analytical instrument (Perkin Elmer, Finland). Group 1 — newborn, the presence of an infectious and inflammatory focus and dysfunction of two or more systems (sepsis), comparable antibacterial therapy for newborns with sepsis. Group 2 — newborns with pneumonia, the presence of an infectious inflammatory focus in the lungs and the absence of organ and systems dysfunction. Group 3 — healthy newborns undergoing examination in the perinatal center
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
